AR 67

Drug Profile

AR 67

Alternative Names: (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin; AR-67; D 67; DB-67

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator University of Pittsburgh
  • Developer Arno Therapeutics; TaiGen Biotechnology; TTY Biopharm
  • Class Antineoplastics; Camptothecins; Organosilicon compounds
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 30 Sep 2016 Vivacitas Oncology acquires AR 67 from Arno Therapeutics
  • 18 May 2012 Arno Therapeutics terminates its licence for AR 67 (Arno Therapeutics Form-10K report May 2012)
  • 01 May 2012 Discontinued - Phase-I for Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top